Nu se va prescrie în regim compensat pentru tratamentul litiazei biliare.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
A05AA02 ACIDUM CAPS. 250 mg
URSODEOXYCHOLICUM
URSOFALK(R) 250 mg DR. FALK PHARMA GMBH
URSOSAN 250 mg PRO. MED. CS PRAHA AS
________________________________________________________________________________
______________________________________________________________________________
| 938 |B01AB05| ENOXAPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti-Xa/0.2 ml
CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS
anti-Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti-Xa/0,4 ml
CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS
anti-Xa/0.4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti-Xa/0.6 ml
CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS
anti-Xa/0.6 ml
B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui
anti-Xa/0.8 ml
CLEXANE 8000 ui 8000 ui anti-Xa/0.8 ml LAB. AVENTIS
anti-Xa/0.8 ml
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti-Xa/0.2 ml
CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS
anti-Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti-Xa/0,4 ml
CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS
anti-Xa/0.4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti-Xa/0.6 ml
CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS
anti-Xa/0.6 ml
________________________________________________________________________________
______________________________________________________________________________
| 939 |B01AB08| REVIPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml
CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
B01AB08 REVIPARINUM SOL. INJ. 3436 ui/0.6 ml
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG
________________________________________________________________________________
______________________________________________________________________________
| 940 |B01AC11| ILOPROSTUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AC11 ILOPROSTUM CONC. PT. SOL. PERF. 20 µg/ml
ILOMEDIN(R) 20 20 µg/ml SCHERING AG
________________________________________________________________________________
______________________________________________________________________________
| 941 |B01AD02| ALTEPLASUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AD02 ALTEPLASUM LIOF. + SOLV. PT. SOL. 50 mg
INJ.
ACTILYSE 50 mg BOEHRINGER INGELHEIM INT.
GMBH
________________________________________________________________________________
______________________________________________________________________________
| 944 |C03EB01| COMBINAŢII (SPIRONOLACTONUM + FUROSEMIDUM) | |
|_______|_______|____________________________________________|_________________|
Electroliţii serici trebuie să fie verificaţi periodic.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
C03EB01 COMBINAŢII CAPS.
(SPIRONOLACTONUM +
FUROSEMIDUM)
DIUREX 50 TERAPIA SA
________________________________________________________________________________
______________________________________________________________________________
| 945 |H01BA02| DESMOPRESSINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
H01BA02 DESMOPRESSINUM
MINIRIN 0,2 mg 0.2 mg FERRING AB
H01BA02 DESMOPRESSINUM COMPR. 0.2 mg
MINIRIN 0,2 mg 0.2 mg FERRING AB
________________________________________________________________________________
______________________________________________________________________________
| 946 |J01CR05| PIPERACILLINUM + TAZOBACTAMUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01CR05 PIPERACILLINUM + LIOF. PT. SOL. INJ.
TAZOBACTAMUM
TAZOCIN 2,25 WYETH LEDERLE PHARMA GMBH
TAZOCIN 4,5 WYETH LEDERLE PHARMA GMBH
________________________________________________________________________________
______________________________________________________________________________
| 947 |J01XX08| LINEZOLIDUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA 100 mg/5 ml
ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM SOL. PERF. 2 mg/ml
ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM COMPR. FILM. 600 mg
ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG
________________________________________________________________________________
______________________________________________________________________________
| 948 |J02AC03| VORICONAZOLUM** | Protocol: J012B |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J02AC03 VORICONAZOLUM COMPR. FILM. 200 mg
VFEND 200 mg 200 mg PFIZER LTD.
J02AC03 VORICONAZOLUM PULB. PT. SOL. PERF. 200 mg
VFEND 200 mg 200 mg PFIZER LTD.
J02AC03 VORICONAZOLUM PULB. PT. SUSP. ORALA 40 mg/ml
VFEND 40 mg/ml 40 mg/ml PFIZER LTD.
J02AC03 VORICONAZOLUM COMPR. FILM. 50 mg
VFEND 50 mg 50 mg PFIZER LTD.
________________________________________________________________________________
______________________________________________________________________________
| 949 |J02AX04| CASPOFUNGINUM** | Protocol: J010D |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 50 mg
SOL. PERF.
CANCIDAS 50 mg 50 mg MERCK SHARP & DOHME LTD
J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 70 mg
SOL. PERF.
CANCIDAS 70 mg 70 mg MERCK SHARP & DOHME LTD
________________________________________________________________________________
______________________________________________________________________________
| 951 |J05AB14| VALGANCICLOVIRUM** | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul de iniţiere şi menţinere pentru retinita cu citomegalovirus (CMV) la pacienţi imunocompromişi.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J05AB14 VALGANCICLOVIRUM COMPR. FILM. 450 mg
VALCYTE(R) 450 mg 450 mg ROCHE ROMANIA SRL
________________________________________________________________________________
______________________________________________________________________________
| 953 |L03AA02| FILGRASTIMUM (G-CSF) | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 30 MU/0.5 ml
NEUPOGEN(R) 30 MU/0.5 ml AMGEN EUROPE B.V.
L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 48 MU/0.5 ml
NEUPOGEN(R) 48 MU/0.5 ml AMGEN EUROPE B.V.
________________________________________________________________________________
______________________________________________________________________________
| 954 |L04AA01| CICLOSPORINUM | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Managementul rejectului de grefă la pacienţii supuşi procedurii de transplant.
Monitorizarea atentă a pacienţilor este obligatorie.
Dostları ilə paylaş: |